Description
FCAR, also called FcalphaRI or CD89, is a type I transmembrane receptor for Fc region of IgA which is the most abundant immunoglobulin in mucosal areas but is only the second most common antibody isotype in serum. This receptor is present on the surface of myeloid lineage cells such as neutrophils, monocytes, macrophages, and eosinophils, especially phagocytes located in mucosal areas. Upon ligand IgA binding, FcalphaRI associates with the FcR gamma signaling molecule bearing the immunoreceptor tyrosine-based activation motif (ITAM) through a unique charge-based mechanism and triggers multiple cell-mediated immune responses. It has been reported that Fc RI is a dual-function receptor that can mediate both inflammatory and anti-inflammatory responses depending on the type of interaction with its ligand. Sustained aggregation of FCAR results in activation of target-cell functions such as antigen presentation and cytokine release. In contrast, Monomeric targeting with serum IgA or with a variety of anti-FcalphaRI Fab fragments triggers an inhibitory response and additionally induces apoptosis. FcalphaRI thus play an fundamental role in preventing tumor development and growth, as well as in controlling inflammation.
This Rat CD89 overexpression lysate was created in HEK293 Cells and intented for use as a Western blot (WB) positive control. Purification of CD89 protein from the overexpression lysate was verified